Cannabis Studies, Multiple Sclerosis
Multiple Sclerosis
The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis.
Cannabinoids may have possible therapeutic properties for the management of the multiple sclerosis.
Recent high quality reviews find cannabinoids may have modest effects in multiple sclerosis for pain or spasticity.
Cannabis extracts have therapeutic potential to slow multiple sclerosis progression and repair the central nervous system.
Cannabis extracts could be capable of attenuating experimental autoimmune encephalitis progression in a multiple sclerosis model.
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
This reviews the evidence, efficacy and effectiveness of THC-CBD oromucosal spray in symptom management for patients with spasticity due to MS.
This review discusses the potential of cannabinoid therapeutics as disease-modifying or symptom control agents for slowing disease progression in MS and ALS.
Treatment with THC/CBD spray appears to be a valid answer to some of the unmet needs in patients with multiple sclerosis.
These findings highlight the anti-inflammatory effects of cannabidiol in this viral model of multiple sclerosis.
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice.
Cannabidiol inhibits symptoms of multiple sclerosis-like disease in mice.
Whole plant cannabis provides subjective symptom relief in multiple sclerosis.
Hemp seed and evening primrose oils with hot-nature diet have beneficial effects in improving the clinical score in multiple sclerosis patients.
Cannabigerol quinone (VCE-003) has high potential for use against MS and perhaps other neuroinflammatory diseases.
Cannabis extracts can be a useful and safe option for patients with MS with moderate to severe spasticity resistant to common antispastic drugs.
Cannabis-based extracts have therapeutic value for bladder dysfunction in advanced multiple sclerosis.
Cannabis-based medicine is effective in reducing pain and sleep disturbance in patients with multiple sclerosis related central neuropathic pain and is mostly well tolerated.
Delta-tetrahydrocannabinol (THC) and cannabidiol have therapeutic value in the management of spasticity associated with multiple sclerosis.
Orally administered cannabis extract may provide a therapeutic option to other drugs in the treatment of spasticity in patients with multiple sclerosis
THC:CBD oromucosal spray provided symptomatic relief of MS spasticity with good tolerability in a relevant number of previously resistant patients.
This study may support the experimental and biological evidence for a neuroprotective effect by the endocannabinoid system in MS.
The present study confirms the efficacy of cannabinoids in reducing spasticity in patients with multiple sclerosis